Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression
暂无分享,去创建一个
S. Davies | M. Allison | M. Vacca | J. Griffin | E. Petsalaki | M. Bohlooly-y | A. Vidal-Puig | S. Virtue | S. Carobbio | A. Acharjee | F. Oakley | D. Lindén | V. Azzu | M. Dale | G. Bidault | J. Leslie | Zoe Hall | A. Lukasik | Ioannis Kamzolas
[1] G. Evan,et al. Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma , 2020, Hepatology.
[2] M. Allison,et al. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease. , 2020, Gastroenterology.
[3] F. Nigsch,et al. Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model , 2019, Hepatology communications.
[4] E. Albano,et al. Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.
[5] P. Escribá,et al. Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues , 2019, International journal of molecular sciences.
[6] Robert V Farese,et al. Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. , 2019, Molecular cell.
[7] Z. Younossi,et al. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.
[8] W. Wahli,et al. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity , 2018, Scientific Reports.
[9] C. Sirlin,et al. Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] Charlotte L. Scott,et al. Macrophages and lipid metabolism , 2018, Cellular immunology.
[11] M. Allison,et al. Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption , 2018, Genome Biology.
[12] Marju Orho-Melander,et al. Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.
[13] A. Feldstein,et al. Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.
[14] T. Luedde,et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.
[15] R. Hammer,et al. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice[S] , 2018, Journal of Lipid Research.
[16] H. Waldmann,et al. The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival , 2018, Front. Immunol..
[17] D. Samuel,et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients , 2017, Scientific Reports.
[18] S. Davies,et al. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease , 2017, Hepatology.
[19] S. Bellentani. The epidemiology of non‐alcoholic fatty liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[20] A. Kennedy,et al. Role of lipids in the metabolism and activation of immune cells. , 2016, The Journal of nutritional biochemistry.
[21] P. Bedossa,et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer , 2016, Journal of hepatology.
[22] Q. Anstee,et al. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.
[23] M. Orešič,et al. Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .
[24] M. Allison,et al. Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD , 2015, Seminars in Liver Disease.
[25] Eoin Fahy,et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S] , 2015, Journal of Lipid Research.
[26] J. Browning,et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.
[27] T. Luedde,et al. Pharmacological inhibition of the chemokine C‐C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly‐6C+ macrophage infiltration in mice , 2014, Hepatology.
[28] M. Raspa,et al. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units , 2014, Laboratory animals.
[29] T. Hibi,et al. Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice , 2014, Hepatology.
[30] C. Lelliott,et al. Adaptive Changes of the Insig1/SREBP1/SCD1 Set Point Help Adipose Tissue to Cope With Increased Storage Demands of Obesity , 2013, Diabetes.
[31] G. Targher,et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[32] M. Vacca,et al. Nuclear receptors in regenerating liver and hepatocellular carcinoma , 2013, Molecular and Cellular Endocrinology.
[33] A. Moschetta,et al. Hepatic‐specific activation of peroxisome proliferator‐activated receptor γ coactivator‐1β protects against steatohepatitis , 2013, Hepatology.
[34] Joan Tordjman,et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.
[35] J. Fallowfield,et al. Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .
[36] H. Guillou,et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. , 2012, The Journal of clinical investigation.
[37] G. Farrell,et al. SREBP‐2: A link between insulin resistance, hepatic cholesterol, and inflammation in NASH , 2011, Journal of gastroenterology and hepatology.
[38] C. Cooper,et al. No association between polymorphisms in the INSIG1 gene and the risk of type 2 diabetes and related traits. , 2010, The American journal of clinical nutrition.
[39] Antonio Vidal-Puig,et al. An allostatic control of membrane lipid composition by SREBP1 , 2010, FEBS letters.
[40] M. Olivier,et al. INSIG1 influences obesity-related hypertriglyceridemia in humans , 2010, Journal of Lipid Research.
[41] Michelle M Wiest,et al. The plasma lipidomic signature of nonalcoholic steatohepatitis , 2009, Hepatology.
[42] Xiaohui Xie,et al. Genome-wide analysis of SREBP-1 binding in mouse liver chromatin reveals a preference for promoter proximal binding to a new motif , 2009, Proceedings of the National Academy of Sciences.
[43] S. Caldwell,et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.
[44] J. Fernandez-Checa,et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. , 2009, Journal of hepatology.
[45] A. Feldstein,et al. Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease , 2009, Journal of Biological Chemistry.
[46] Z. Younossi,et al. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. , 2008, Journal of hepatology.
[47] C. Kendziorski,et al. Publishes Results of a Wide Variety of Studies from Human and from Informative Model Systems with Physiological Genomics , 2003 .
[48] Michelle M Wiest,et al. A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.
[49] N. Fausto,et al. Liver regeneration , 2006, Hepatology.
[50] R. Hammer,et al. Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. , 2005, The Journal of clinical investigation.
[51] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[52] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[53] H. Tsukamoto,et al. Adipogenic Transcriptional Regulation of Hepatic Stellate Cells* , 2005, Journal of Biological Chemistry.
[54] J. Doyle,et al. Metabolic syndrome and robustness tradeoffs. , 2004, Diabetes.
[55] Jinping Li,et al. Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Hammer,et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. , 2004, The Journal of clinical investigation.
[57] Jay D. Horton,et al. Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus* , 1999, The Journal of Biological Chemistry.
[58] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[59] R. Hammer,et al. Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N). , 1998, The Journal of clinical investigation.
[60] A. Hamsten,et al. Human evidence for the involvement of insulin-induced gene 1 in the regulation of plasma glucose concentration , 2006, Diabetologia.
[61] J. Goldstein,et al. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. , 2003, Molecular cell.
[62] O. R-CH2-CH2-CH,et al. FATTY acid oxidation. , 1946, Nutrition reviews.